期刊文献+

盐酸帕洛诺司琼用于麻醉术后止吐的效果观察 被引量:2

Therapeutic Observation of Palonosetron Hydrochloride for Vomiting after Anesthesia Surgery
原文传递
导出
摘要 目的:观察盐酸帕洛诺司琼用于麻醉术后出现的急性及迟发性呕吐的疗效和不良反应。方法:选择腹腔镜胆囊切除手术的60例患者,随机分为试验组与对照组,每组30例,在麻醉诱导前,试验组给予盐酸帕洛诺司琼0.25mg,对照组给予盐酸托烷司琼5mg,分别记录2组麻醉术后72h内止吐效果和不良反应。结果:试验组与对照组对麻醉术后出现急性呕吐的完全控制率分别为80.0%、70.0%(P>0.05),急性呕吐发生率均为13.3%,但迟发性呕吐发生率分别为6.7%、16.7%(P<0.05);2组主要不良反应为腹胀、头痛及便秘,试验组与对照组的总不良反应发生率分别为23.3%、20.0%(P>0.05)。结论:2种5-羟色胺3(5-HT3)受体拮抗药均有较好的止吐作用,而盐酸帕洛诺司琼对于迟发性呕吐效果更好。 OBJECTIVE: To observe therapeutic efficacy and adverse drug reaction of palonosetron hydrochloride for acute and delayed vomiting after anesthesia surgery. METHODS: 60 patients with laparoscopic cholecystectomy were randomly divided into test group and control group with 30 patients in each group. Before induction of anesthesia, test group was given palonosetron hy- drochloride 0.25 mg and control group was given tropisetron hydrochloride 5 mg. Antiemetic effects and adverse drug reactions of 2 groups were recorded within 72 h after surgery. RESULTS: The complete control rates of acute vomiting in test group and control group after anesthesia surgery were 80.0% and 70.0% respectively (P〉0.05), the incidence of acute vomiting was 13.3% and that of delayed vomiting were 6.7% and 16.7% respectively (P〈Z0.05) ; main adverse drug reactions were bloating, headache and con- stipation in 2 groups and the incidences of adverse drug reaction were 23.3% and 20.0% (P〉0.05). CONCLUSION: These two 5-HT3 receptor antagonists both have good antiemetic effect, but palonosetron hydrochloride is better in the treatment of delayed vomiting.
机构地区 解放军第
出处 《中国药房》 CAS CSCD 2012年第34期3226-3228,共3页 China Pharmacy
关键词 盐酸帕洛诺司琼 盐酸托烷司琼 恶心 呕吐 麻醉 药物疗效 Palonosetron hydrochloride Tropisetron hydrochloride Nausea Vomiting Anesthesia Therapeutic efficacy
  • 相关文献

参考文献12

二级参考文献55

  • 1谢勉,吴海鹰,郭颖,刘俊玲,管忠震,刘亚利,王平辉,陈强,黄萍,杨健伟.国产和进口盐酸托烷司琼防治化疗所致恶心、呕吐的随机对照临床研究[J].癌症,2005,24(8):998-1001. 被引量:9
  • 2陈艳,丁莉坤,孟玲燕,丁黎,杨林,文爱东.盐酸帕洛诺司琼注射液人体药动学研究[J].中国新药杂志,2007,16(10):806-809. 被引量:14
  • 3Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach[J]. Support Care Cancer, 2002,10 : 519-522.
  • 4Geling O, Eichler HG. Should 5 hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis Systematic re-evaluation of clinical evidence and drug cost implications[J]. J Clin Oncol, 2005,23(6): 1289-1294.
  • 5Gralla R, Lichinitser M, Vegt SV, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double blind randomized phase 111 trial comparing single doses of palonosetron with ondansetron[J]. Ann of Oncol,2003, 14 (10) : 1570-1577.
  • 6Einhorn LH,Brames MJ,Dreicer R,et al.Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer[J].Support Care Cancer,2007,15(11):1293-13130.
  • 7Rojas C,Thomas AG,Alt J,et al.Palonosetron triggers 5-HT(3)receptor internalization and causes prolonged inhibition of receptor function[J].Eur J Pharmacol,2010,626(2/3):193-199.
  • 8Segawa Y,Aogi K,Inoue K,et al.A phase Ⅱ dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy,including anthracyeline and cyclophosphamidebased chemotherapy[J].Ann Oncol,2009 20(11):1874-1880.
  • 9Maemondo M,Masuda N,Sekine I,et al.A phase Ⅱ study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy[J].Ann Oncol,2009,20(11):1860-1866.
  • 10Navari RM.Palonosetron:a second generation 5-hydroxytryptamine 3 receptor antagonist[J].Expert Opin Drug Metab Toxicol,2009,5(12):1577-1586.

共引文献44

同被引文献11

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部